Key Insights

Highlights

Success Rate

72% trial completion

Published Results

12 trials with published results (14%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

15.1%

13 terminated out of 86 trials

Success Rate

72.3%

-14.2% vs benchmark

Late-Stage Pipeline

6%

5 trials in Phase 3/4

Results Transparency

35%

12 of 34 completed with results

Key Signals

12 with results72% success13 terminated

Data Visualizations

Phase Distribution

75Total
Not Applicable (30)
Early P 1 (4)
P 1 (19)
P 2 (17)
P 3 (5)

Trial Status

Completed34
Active Not Recruiting17
Recruiting14
Terminated13
Withdrawn7
Not Yet Recruiting1

Trial Success Rate

72.3%

Benchmark: 86.5%

Based on 34 completed trials

Clinical Trials (86)

Showing 20 of 20 trials
NCT07391774Phase 3Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

NCT04816006Not ApplicableRecruiting

Breast Cancer, Reasoning, and Activity Intervention

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT05812807Phase 3Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT07259304Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT05368428Not ApplicableTerminated

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

NCT04001829Phase 2Active Not Recruiting

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT05319873Phase 1Active Not Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

NCT05379153Phase 3Recruiting

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

NCT05452681Not ApplicableTerminated

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors

NCT05243056Not ApplicableTerminated

A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

NCT04266249Phase 2Active Not Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT05455658Phase 2Active Not Recruiting

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

NCT05049746Not ApplicableActive Not Recruiting

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

NCT06538389Phase 2Recruiting

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT03218826Phase 1Completed

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT07331077Not ApplicableNot Yet Recruiting

A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial

NCT02918474Not ApplicableRecruiting

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

NCT04678414Active Not Recruiting

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer

NCT04993313Not ApplicableActive Not Recruiting

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

Scroll to load more

Research Network

Activity Timeline